Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour (PIL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01398696 |
Recruitment Status :
Completed
First Posted : July 20, 2011
Last Update Posted : October 12, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastroenteritis Pharyngitis | Procedure: Patient Information Leaflets Procedure: usual consultation | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour : a Randomised Controlled Trial in Primary Care. |
Study Start Date : | November 2009 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Patient Information Leaflets
Patient Information Leaflets (PIL) is given to the patient during consultation
|
Procedure: Patient Information Leaflets
Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room |
Placebo Comparator: usual consultation without PIL
no particular intervention during consultation for the patient.
|
Procedure: usual consultation
No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given |
- The primary outcome measure was the mean behaviour score [ Time Frame: In ten to fifteen days after patient after the visit ]All patients were called, ten to fifteen days after the visit, to answer a questionnaire on their behaviour related to the disease since they visited the GP. It permitted to calculate a behaviour score. Better was the score, better was the patient's behaviour related to his disease.
- the mean comprehension score [ Time Frame: in ten to fifteen days after the visit ]All patients (or their parent) were called, ten to fifteen days after the visit, to answer a questionnaire on their comprehension related to the disease since they visited the GP. It permitted to calculate a comprehension score. Better was this score, better was the patient's comprehension.
- number of visit of patient's family for the same pathology [ Time Frame: in ten to fifteen days after the visit ]we get the information by a phone call to the patient, in ten to fifteen days after the visit

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patient.
- Minor child accompanied by a responsible adult.
- The patient or the caregiver must be reachable by telephone within ten to fifteen days following the consultation.
Exclusion Criteria:
- Illiterate patient
- Patient refusing follow-up call.
- Patient with visual or hearing impairment.
- Patient non-Francophone.
- Private patient of liberty by judicial or administrative.
- Person being a measure of legal protection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01398696
France | |
General practitioner office | |
Antibes Juan Les Pins, France | |
General practitioner office | |
Beaulieu Sur Mer, France | |
General practitioner office | |
Chambery, France | |
General practitioner office | |
Charolles, France | |
General practitioner office | |
Chirens, France | |
General practitioner office | |
Coublevie, France | |
General practitioner office | |
Echirolles, France | |
General practitioner office | |
Grenoble, France, 38000 | |
University Hospital Grenoble | |
Grenoble, France | |
General practitioner office | |
La Buisse, France | |
General practitioner office | |
La Murette, France | |
General practitioner office | |
Lyon, France | |
General practitioner office | |
Massy, France | |
General practitioner office | |
Megeve, France | |
General practitioner office | |
Plessis Robinson, France | |
General practitioner office | |
Saint Etienne de Crossey, France | |
General practitioner office | |
Saint Marcellin, France | |
General practitioner office | |
Saint Martin D'heres, France | |
General practitioner office | |
Saint Priest, France | |
General practitioner office | |
Saint Sorlin, France | |
General practitioner office | |
Ugine, France | |
General practitioner office | |
Valence, France | |
General practitioner office | |
Voiron, France |
Study Director: | Melanie Sustersic, GP | University Hospital, Grenoble | |
Study Director: | Jean-Luc Bosson, PHD | University Hospital, Grenoble | |
Principal Investigator: | LUCILE REIN, MD | University Hospital, Grenoble | |
Principal Investigator: | EVA JEANNET, MD | University Hospital, Grenoble |
Other Publications:
Responsible Party: | University Hospital, Grenoble |
ClinicalTrials.gov Identifier: | NCT01398696 |
Other Study ID Numbers: |
n° IRB 5891 |
First Posted: | July 20, 2011 Key Record Dates |
Last Update Posted: | October 12, 2011 |
Last Verified: | October 2011 |
Patient Information Leaflets primary care patient behaviour pharyngitis gastroenteritis |
Pharyngitis Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Respiratory Tract Infections |
Infections Pharyngeal Diseases Stomatognathic Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases |